Mefiron Tablet 4 mg (Methylprednisolone)

Adult dosage

1. The initial dose may vary from 4mg to 48mg of methylprednisolone per day, depending on the symptoms of the specific disease. In general, a low dose is sufficient for less severe conditions, but a high initial dose may be required in certain patients. The initial dose should be maintained or adjusted until a satisfactory response is achieved. If a satisfactory clinical result is not achieved after a reasonable period, treatment should be discontinued and replaced with another appropriate treatment. The dose must be determined individually according to the various diseases being treated and the patient's response. Once an adequate response is achieved, an appropriate maintenance dose should be determined by reducing the initial dose at suitable intervals until the lowest dose that maintains an adequate clinical response is reached. Ongoing monitoring of the dose is required. Situations that may require dose adjustment include improvement or worsening of the disease, individual patient response to the medicine, and the effect on the patient of exposure to stressful conditions unrelated to the symptoms of the disease being treated. In the latter case, it may be necessary to increase the dose for a period sufficient to achieve satisfactory control of the patient's condition. After long-term treatment, gradual dose reduction is recommended when discontinuing the medicine. 2. Multiple sclerosis For treatment of acute exacerbations of multiple sclerosis, it is effective to administer prednisolone 200mg daily for 1 week, followed by prednisolone 80mg every other day for 1 month (4mg of methylprednisolone is equivalent to 5mg of prednisolone). 3. ADT (Alternate Day Therapy) Alternate day therapy is a regimen in which twice the daily dose is administered on one morning every other day. The initial suppressive dose should be continued until a satisfactory clinical response is achieved, usually for 4 to 10 days in many allergic and collagen diseases. ① Convert to ADT and gradually reduce the amount of corticosteroid given on alternate days. ② Reduce the daily corticosteroid dose to the minimum effective dose as soon as possible, according to control of disease progression, and then switch to an alternate-day schedule. In theory, approach ① is more desirable. If this is difficult, it is preferable to administer 3 times, or even 4 times, the daily dose on alternate days rather than simply doubling the daily dose. Once the patient's condition is controlled again, attempt to reduce this dose to the minimum. If an acute exacerbation occurs during disease progression, it may be necessary to return to a fully suppressive dose of corticosteroid divided over the day to achieve control. Once control is achieved, the established alternate-day regimen may be attempted again.

This medication should not be used in patients who have a history of specific allergic reactions or hypersensitivity to its components. This drug may suppress immune function, and administering it to patients with infections without appropriate antibacterial agents or systemic fungal infections may increase the risk of worsening the infection. It should not be used in patients with viral infections such as herpes simplex, shingles, and chickenpox, and it should also be avoided in patients receiving live vaccines or attenuated live vaccines. This medication contains lactose, and should not be administered to patients with lactose intolerance or related genetic diseases. Patients with a history of glaucoma, tuberculous disease, posterior capsule cataracts, hypertension, thrombosis, or acute myocardial infarction should use this medication with caution, and careful monitoring is required as symptoms may worsen. Special caution is also needed when administering this drug to patients with peptic ulcers, psychiatric disorders, severe osteoporosis, diabetes, renal failure, hypothyroidism, fatty liver, and elderly patients. Various side effects such as fluid retention, edema, increased blood pressure, muscle weakness, osteoporosis, gastrointestinal disorders, skin reactions, and neurological disorders may occur, so symptoms should be closely monitored during use. Long-term administration may lead to adrenal insufficiency, and abrupt discontinuation of treatment can be dangerous; dosages should be gradually reduced. In cases of stress such as trauma, surgery, or infection during administration, it may be necessary to temporarily increase the dosage. Due to immune function suppression, susceptibility to infections may be increased, so exposure to infectious diseases such as chickenpox or measles should be avoided, and immediate consultation with healthcare professionals is advised if infection is suspected. This medication may interact with various drugs, so patients taking other medications should inform their doctor or pharmacist. Women who are pregnant or may become pregnant should only use this medication when absolutely necessary due to potential effects on the fetus, and breastfeeding should be avoided during treatment. In children, side effects such as growth retardation may occur, so the lowest effective dosage should be used and growth should be monitored closely. Elderly patients have an increased risk of side effects such as infections, diabetes, osteoporosis, and glaucoma, so careful administration and close monitoring are required.

Edema, sodium retention, potassium loss, fluid retention, hypokalemic alkalosis, congestive heart failure, hypertension, myasthenia, aseptic necrosis of the femoral and humeral heads, steroid myopathy, loss of muscle mass, pathologic fractures of the pelvis, osteoporosis, spinal compression fractures, arthralgia, tendon rupture, increased ALT, increased AST, increased ALP, nausea, thirst, vomiting, abdominal pain, anorexia, increased appetite, peptic ulcer, abdominal distension, pancreatitis, ulcerative esophagitis, diarrhea, delayed wound healing, facial erythema, thin and fragile skin, abnormal sweating, petechiae, purpura, suppression of skin reactions, purpura, acne, hypertrichosis, alopecia, pigmentation, nipple edema, increased intracranial pressure, seizures, dizziness, headache, insomnia, euphoria, depression, Cushing's syndrome, menstrual irregularities, growth retardation in children, symptoms of latent diabetes mellitus, secondary adrenal insufficiency, pituitary unresponsiveness, reduced glucose tolerance, increased demand for insulin or oral hypoglycemic agents, suppression of adrenocorticotropic hormone secretion, increased intraocular pressure, glaucoma, posterior capsule opacification, secondary eye infections, retinal disorders, proptosis, negative nitrogen balance, immune system disorders, allergic reactions, shock, urticaria, anaphylactic reactions, hypersensitivity reactions

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is advisable to maintain storage temperatures between 1 degree and 30 degrees Celsius at room temperature. This helps to preserve the medication's efficacy and safety over time.

Appearance

White oval tablet

Package unit

30 tablets/bottle, 500 tablets/bottle